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M IM ICKING ‘M OLECULAR M ACH IN E’ MAY BE KEY
TO CREATING AN EFFECTIV E VACCINE AGAINST HIV/AIDS
University of M ontana Virologist Receives AmFAR G ran t for Novel A pproach

by Caroline Lupfer K urtz
University Relations
MISSOULA A way to mimic the complex surface interactions between human immunodeficiency virus and
the immune-system cells it attacks may turn out to be the key to an effective vaccine against HIV and its
progression into AIDS, a University of Montana-Missoula researchers says.
The American Foundation for AIDS Research (AmFAR) recently awarded a $142,456 grant to
virologist Jack H. Nunberg, and UM’s HIV Research Laboratory to develop and test his novel ideas for
an effective HIV vaccine. AmFAR is the nation’s leading nonprofit organization dedicated to the
support of AIDS research, prevention, and development of sound public policy. Nunberg hopes that
this new approach will lead to antibodies that can neutralize the type of virus that appears in infected
individuals, as opposed to laboratory strains.
“Research has shown that people infected with HIV produce antibodies that often can neutralize
the virus. We believe that if we can produce these antibodies prior to exposure to HIV, then we will be
able to protect against the establishment of infection and disease,” said Nunberg, who also is a professor
of biological sciences and director of the Montana Biotechnology Center at the University.
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To date, scientists have produced and tested candidate HIV vaccines made up of genetically
engineered pieces, or subunits, of the virus’s outer protein envelope. Antibodies engendered by these
vaccines are able to block the infection of cells by laboratory strains of HIV, but uniformly fail to block
the “primary isolate” form of the virus -- that is, virus taken directly from infected patients, or “street
virus.” Nunberg believes that current vaccine strategies fail because the viral subunits are presented in
a static and nonfunctioning form.
“By contrast, viral envelope protein in infected people interacts with a series of receptors and
coreceptors on human T cells,” Nunberg said. His approach attempts to present HIV envelope proteins
in the midst of actively binding with key molecules on the surface of immune cells.
During infection, HIV envelope protein first binds to a type of protein molecule, called CD4, on
the surface of certain “helper” T lymphocytes, which mediate the immune response to invading
pathogens. Helper T cells are the primary target of HIV attack. A number of other, recently identified
cell-surface molecules, known as coreceptors, then become involved in order to enable the virus to fuse
with and enter the target cell. Nunberg believes that to raise an effective immune response the body
must see the “moving machine” —the movements and changes involved in virus-cell binding and fusion.
“I think of the HIV envelope protein as a molecular machine that orchestrates this complex
process, much like a space shuttle going through the series of steps required to dock with a space
station,” Nunberg said. “We believe that it is somewhere in this process that HIV is vulnerable to
antibody attack. If we can mimic this process by using ‘fusion-competent’ vaccine strategies, then
perhaps we can mimic the type of neutralizing antibodies engendered by active infection.”
Nunberg, graduate student Rachel LaCasse, senior research associate Kathryn Follis, and post
doctoral fellow Meg Trahey are developing and testing a series of vaccines made up of both functional
HIV envelope protein and the T cell receptor molecules required for virus-cell binding and fusion.
When combined in a vaccine, these components undergo the same binding and fusion reactions as seen
in active HIV infection. Specially engineered transgenic mice, developed by Dr. Dan R. Littman and
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colleagues at the University of California at San Francisco and the Skirball Institute of Biomolecular
Medicine at New York University, will be used in this work. Initial studies have used cells captured
during the process of fusion. Subsequent studies, in collaboration with Gail Mazzara and Dennis
Panicali at Therion Biologies Corporation in Cambridge, Mass., will use genetically engineered vaccinia
viruses to deliver a fusion-competent vaccine.
“Antiviral drugs developed in the past three years are giving people with HIV a new lease on
life, at least for a while,” Nunberg said. “But unfortunately these are not cures and they do not protect
people from infection.”
According to AmFAR, the need for an effective HIV vaccine has never been greater.
Worldwide, more than 30 million people have been infected with HIV, and each day some 16,000 new
infections occur with nearly 90 percent of those in developing countries, according to the World Health
Organization. In the United States, an estimated 40,000 to 80,000 new infections occur each year.
“In funding our work, AmFAR is sharing the risks in this novel approach to HIV vaccine
development. We appreciate their confidence and with their help are eager to explore new avenues to
develop this urgently needed vaccine,” Nunberg said.
“As with other infectious diseases, we want to be able to protect against infection rather than
treat after the fact. Vaccine campaigns have worked. W e’ve eradicated smallpox, and polio is targeted
for eradication over the next few years. Many childhood diseases in the developed world, such as
measles, mumps, rubella, diphtheria, pertussis, are history. I believe, and AmFAR believes, the only
hope in controlling the worldwide HIV epidemic is through immunization.”
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